The 10-second takeaway
For the quarter ended March 31 (Q1), CR Bard beat slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share contracted. GAAP earnings per share contracted significantly.
Margins dropped across the board.
CR Bard reported revenue of $740.3 million. The 17 analysts polled by S&P Capital IQ anticipated a top line of $729.5 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.44. The 19 earnings estimates compiled by S&P Capital IQ anticipated $1.42 per share. Non-GAAP EPS of $1.44 for Q1 were 11% lower than the prior-year quarter's $1.61 per share. GAAP EPS of $1.08 for Q1 were 33% lower than the prior-year quarter's $1.60 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.1%, 160 basis points worse than the prior-year quarter. Operating margin was 22.9%, 450 basis points worse than the prior-year quarter. Net margin was 12.3%, 670 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $749.6 million. On the bottom line, the average EPS estimate is $1.46.
Next year's average estimate for revenue is $3.06 billion. The average EPS estimate is $6.29.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 270 members out of 279 rating the stock outperform, and nine members rating it underperform. Among 102 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 101 give CR Bard a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CR Bard is hold, with an average price target of $104.75.
Is CR Bard the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add CR Bard to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.